Drug Approval | December 04, 2025
FDA nod to priority review to AstraZeneca’s Baxdrostat for hard-to-control hypertension
Here's a development that aims to keep your blood pressure in check. Literally!
Here's a development that aims to keep your blood pressure in check. Literally!
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The medicine was well tolerated, with no unexpected safety issue
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Subscribe To Our Newsletter & Stay Updated
